Metastatic castration-resistant prostate cancer: The emerging continuum of care

Fred Saad¹

Affiliations

¹ Chairman, National Cancer Institute of Canada Clinical Trials Genitourinary Group (NCIC-CTG G-U) and Canadian Urologic Oncology Group (CUOG); Professor and Chief of Urology, Director of Urologic Oncology, Endowed Chair in Prostate Cancer, Centre Hospitalier de l'Université de Montréal, Montreal, QC.

Fred Saad. Can Urol Assoc J. 2013 Jan-Feb.

. 2013 Jan-Feb;7(1-2 Suppl 1):S3.

doi: 10.5489/cuaj.229.

Fred Saad¹

¹ Chairman, National Cancer Institute of Canada Clinical Trials Genitourinary Group (NCIC-CTG G-U) and Canadian Urologic Oncology Group (CUOG); Professor and Chief of Urology, Director of Urologic Oncology, Endowed Chair in Prostate Cancer, Centre Hospitalier de l'Université de Montréal, Montreal, QC.

No abstract available

Cited by

Altered glucuronidation deregulates androgen dependent response profiles and signifies castration resistance in prostate cancer.
Zimmer BM, Howell ME, Ma L, Enders JR, Lehman D, Corey E, Barycki JJ, Simpson MA. Zimmer BM, et al. Oncotarget. 2021 Sep 14;12(19):1886-1902. doi: 10.18632/oncotarget.28059. eCollection 2021 Sep 14. Oncotarget. 2021. PMID: 34548906 Free PMC article.

1. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12. doi: 10.1056/NEJMoa040720. - DOI - PubMed
1. Saad F, Hotte SJ. Guidelines for the management of castrate-resistant prostate cancer. Can Urol Assoc J. 2010;4:380–4. doi: 10.5489/cuaj.10167. - DOI - PMC - PubMed
1. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54. doi: 10.1016/S0140-6736(10)61389-X. - DOI - PubMed
1. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005. doi: 10.1056/NEJMoa1014618. - DOI - PMC - PubMed
1. Saad F, Asselah J. Chemotherapy for prostate cancer: clinical practice in Canada. Can Urol Assoc J. 2013;7:S5–S10. doi: 10.5489/cuaj.12284. - DOI - PMC - PubMed